



Mylan's Bertek & Cumberland Pharmaceuticals Announce Promotion Agreement

PITTSBURGH & NASHVILLE--(BUSINESS WIRE)--Feb. 5, 2002--Mylan Laboratories Inc. (NYSE:MYL) announced today that its branded division, Bertek Pharmaceuticals Inc., and Cumberland Pharmaceuticals Inc. have signed an agreement for Cumberland to co-promote Kristalose® in the United States.

"We are excited to have Cumberland join us in the promotion of Kristalose®," says James Mauzey, President of Bertek Pharmaceuticals. "Cumberland was selected from a group of companies based on its distinguishing strategy in the pharmaceutical industry. Their ability to penetrate key specialty groups will undoubtedly enhance Kristalose® sales."

"This agreement to promote and sell an established and proven product is an excellent commercial opportunity for our company," says A. J. Kazimi, Cumberland's CEO. "We have been very deliberate in the process of identifying products for our portfolio, and are in position to immediately facilitate increased sales of Kristalose®. We also continue to explore other potential agreements and look forward to enhancing our position in key target markets."

Kristalose® is a proprietary prescription laxative and the brand name for a unique crystalline form of lactulose. This distinctive formulation of a widely used product is designed to enhance patient acceptance and compliance. The drug competes in a growing \$85 million annual U.S. market.

Cumberland Pharmaceuticals Inc. is a Tennessee-based company formed to acquire and market a portfolio of niche pharmaceuticals to specific physician segments such as gastroenterology, critical care, pulmonology and emergency medicine. The company also partners with Vanderbilt University and the State of Tennessee in Cumberland Emerging Technologies Inc., which provides Cumberland Pharmaceuticals access to a pipeline of new pharmaceutical products. For more information visit www.cumberlandpharma.com.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription pharmaceutical products. The Company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through its Bertek Pharmaceuticals Inc. subsidiary. For more information, visit www.mylan.com.

Bertek Pharmaceuticals Inc., based in Research Triangle Park, N.C., develops, licenses and markets proprietary pharmaceuticals for Mylan, with a current focus on dermatology, neurology and cardiology. For more information visit www.bertek.com.